Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK ...

Moderna (MRNA) is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot. The company said ...

The company's president Stephen Hoge will take charge of sales as well as medical and research affairs, according to the report. Bancel will remain in his role as Moderna's CEO, the report added.

Moderna (MRNA) concluded the recent trading session at $54.36, signifying a -0.66% move from its prior day's close. Pharmaceutical company Moderna (MRNA) has seen its stock slump in recent months.